---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009856"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:05:03.005201+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved

## Summary
- Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).
- Cash at Dec 31, 2022 $3.1M, down from $12.3M year ago; raised $3M post-year-end at $0.84/share.
- R&D expenses Q4 $6.4M (up from $2.2M prior year); FY $19.8M (up from $4.7M prior year) due to clinical trials.
- Clinical progress: PF614 oral HAP study database locked Feb 2023; FDA guidance supports acute pain indication; PF614-MPAR Phase 1 fully enrolled.

## SEC filing metadata
- accession: 0001493152-23-009856
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009856
- JSON: https://secwatch.observer/filing/0001493152-23-009856.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009856.txt

## Key facts
- Earnings Releases
  Ensysce Biosciences, Inc. reported the fourth quarter of 2022 results: net income $5.5 million.
  - Period: the fourth quarter of 2022
  - Net income: $5.5 million
  - Result: reported results
  source text: Net loss for the fourth quarter of 2022 was $5.5 million compared to $10.0 million for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm
- Earnings Releases
  Ensysce Biosciences, Inc. reported the full year of 2022 results: net income $24.2 million.
  - Period: the full year of 2022
  - Net income: $24.2 million
  - Result: reported results
  source text: For the full year of 2022, net loss was $24.2 million compared to $29.1 million for the full year of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.